The peptic ulcer and gastro-oesophageal reflux diseases (GORD) medicine sales in Canada are projected to slightly decline from CAD 867.1 million in 2024 to CAD 842.7 million by 2028. This indicates a gradual year-on-year decrease, with a compound annual growth rate (CAGR) reflecting a negative trend over the five-year forecast period. Based on historical data, these figures suggest a stabilizing but slightly shrinking market.

Future trends to watch:

Advancements in alternative therapies and their potential impact on traditional medication sales.
Government policies and healthcare reforms influencing drug prices and sales volumes.
Emerging competition from generic medication manufacturers.
Increasing consumer awareness and self-medication practices.